AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12014900 — intervention group
Group type: EXPERIMENTAL
Intervention: HW with non-antiseptic soap for 30 seconds (US30)
Number of subjects: 43
Study 12014900 — intervention group
Group type: EXPERIMENTAL
Intervention: HW with antiseptic soap for 10 seconds (AS10)
Number of subjects: 43
Study 12014900 — intervention group
Group type: EXPERIMENTAL
Intervention: HW with antiseptic soap for 30 seconds (AS30)
Number of subjects: 43
Study 12014900 — intervention group
Group type: EXPERIMENTAL
Intervention: HW with antiseptic soap for 60 seconds (AS60)
Number of subjects: 43
Study 12014900 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based handrub (ABH)
Number of subjects: 43
Study 12014900 — intervention group
Group type: COMPARATOR
Intervention: HW with non-antiseptic soap (US)
Number of subjects: 43
Study 12014900 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-HH specimens
Number of subjects: 43
Study 10443327 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular insulin injected 5 minutes before meals
Number of subjects: 15
Study 10443327 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin injected 30 minutes before meals
Number of subjects: 15
Study 7797697 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative research utilization model
Number of subjects: 0
Study 7797697 — intervention group
Group type: COMPARATOR
Intervention: Control group (no participation in the model)
Number of subjects: 0
Study 2378593 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (Group A)
Number of subjects: 121
Study 2378593 — intervention group
Group type: COMPARATOR
Intervention: ENTONOX (Group B)
Number of subjects: 121
Study 2378593 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (Group C)
Number of subjects: 121
Study 2378593 — intervention group
Group type: COMPARATOR
Intervention: ENTONOX (Group D)
Number of subjects: 121
Study 2378593 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 121
Study 2378593 — intervention group
Group type: COMPARATOR
Intervention: ENTONOX
Number of subjects: 121
Study 760446 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous heparin therapy
Number of subjects: 80
Study 760446 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent heparin therapy
Number of subjects: 80
Study 760446 — intervention group
Group type: COMPARATOR
Intervention: Overall group (both therapies)
Number of subjects: 80
Study 760446 — intervention group
Group type: COMPARATOR
Intervention: Soft-tissue trauma patients
Number of subjects: 80
Study 31226195 — intervention group
Group type: EXPERIMENTAL
Intervention: Equicrestal level (E group)
Number of subjects: 30
Study 31226195 — intervention group
Group type: COMPARATOR
Intervention: Supracrestal level (SP group)
Number of subjects: 30
Study 31226195 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (E and SP)
Number of subjects: 30
Study 29059635 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (100 mg, once daily)
Number of subjects: 526
Study 29059635 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 526
Study 25952455 — intervention group
Group type: EXPERIMENTAL
Intervention: Bag Valve Mask (BVM)
Number of subjects: 20
Study 25952455 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Tube (LT)
Number of subjects: 20
Study 23168347 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based intervention
Number of subjects: 71
Study 23168347 — intervention group
Group type: COMPARATOR
Intervention: Knowledge-based intervention
Number of subjects: 71
Study 22065255 — intervention group
Group type: COMPARATOR
Intervention: Standard Medical Management (SMM)
Number of subjects: 653
Study 22065255 — intervention group
Group type: EXPERIMENTAL
Intervention: SMM plus opioid dependence counseling
Number of subjects: 653
Study 22065255 — intervention group
Group type: COMPARATOR
Intervention: Extended buprenorphine-naloxone treatment (week 12)
Number of subjects: 653
Study 22065255 — intervention group
Group type: EXPERIMENTAL
Intervention: SMM plus opioid dependence counseling during extended treatment
Number of subjects: 653
Study 22065255 — intervention group
Group type: COMPARATOR
Intervention: Postmedication follow-up (week 24)
Number of subjects: 653
Study 22065255 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmedication follow-up (week 24) with counseling
Number of subjects: 653
Study 19321573 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (83 microg/d)
Number of subjects: 200
Study 19321573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 17482105 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 0
Study 17482105 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study 15243011 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaifenesin
Number of subjects: 34
Study 15243011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 11940618 — intervention group
Group type: EXPERIMENTAL
Intervention: Paratendinous nailing
Number of subjects: 50
Study 11940618 — intervention group
Group type: COMPARATOR
Intervention: Transtendinous nailing
Number of subjects: 50
Study 9864127 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution (LR) with Morgan therapeutic lens (MTL)
Number of subjects: 61
Study 9864127 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced salt solution (BSS Plus) with Morgan therapeutic lens (MTL)
Number of subjects: 61
Study 9864127 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (NSS) with Morgan therapeutic lens (MTL)
Number of subjects: 61
Study 9864127 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LR) without Morgan therapeutic lens (MTL)
Number of subjects: 61
Study 9864127 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (BSS Plus) without Morgan therapeutic lens (MTL)
Number of subjects: 61
Study 9864127 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (NSS) without Morgan therapeutic lens (MTL)
Number of subjects: 61
Study 9864127 — intervention group
Group type: EXPERIMENTAL
Intervention: Morgan therapeutic lens (MTL)
Number of subjects: 61
Study 9864127 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular irrigation solutions (LR, BSS Plus, NSS)
Number of subjects: 61
Study 9864127 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular irrigation with MTL
Number of subjects: 61
Study 8919570 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer screening (various modalities); specific details on dosage and duration not available.
Number of subjects: 0
Study 8919570 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer simulation model; specific details on intervention not available.
Number of subjects: 0
Study 2191990 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled bitolterol (three puffs, 1110 micrograms)
Number of subjects: 40
Study 2191990 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (two puffs, 180 micrograms)
Number of subjects: 40
Study 2191990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15186986 — intervention group
Group type: EXPERIMENTAL
Intervention: Success feedback condition
Number of subjects: 120
Study 15186986 — intervention group
Group type: COMPARATOR
Intervention: Failure feedback condition
Number of subjects: 120
Study 15186986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive beliefs (expectancy and attribution)
Number of subjects: 120
Study 15186986 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy and luck
Number of subjects: 120
Study 31132779 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and Alternative Medicines (CAMs)
Number of subjects: 200
Study 28085022 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain (WG) foods (80 g/day)
Number of subjects: 179
Study 28085022 — intervention group
Group type: COMPARATOR
Intervention: Refined-grain (RG) foods (80 g/day)
Number of subjects: 179
Study 28085022 — intervention group
Group type: EXPERIMENTAL
Intervention: Both WG and RG groups
Number of subjects: 179
Study 28085022 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain (WG) foods
Number of subjects: 179
Study 25752438 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg VIA-2291 for 24 weeks
Number of subjects: 52
Study 25752438 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 52
Study 23447044 — intervention group
Group type: EXPERIMENTAL
Intervention: Myrtol® 300 mg 4 times daily
Number of subjects: 413
Study 23447044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study 23447044 — intervention group
Group type: EXPERIMENTAL
Intervention: Myrtol®
Number of subjects: 413
Study 21145264 — intervention group
Group type: EXPERIMENTAL
Intervention: AorfixTM endovascular stent graft
Number of subjects: 30
Study 19268886 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Number of subjects: 18
Study 19268886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 18
Study 19268886 — intervention group
Group type: COMPARATOR
Intervention: Comparison of imaging methods
Number of subjects: 18
Study 17289683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer (ET)
Number of subjects: 300
Study 17289683 — intervention group
Group type: COMPARATOR
Intervention: Blind embryo transfer (ET)
Number of subjects: 300
Study 15058377 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrisorb barrier (n = 22; group A)
Number of subjects: 30
Study 15058377 — intervention group
Group type: COMPARATOR
Intervention: Resolut XT barrier (n = 18; group B)
Number of subjects: 30
Study 11279374 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg (Group T)
Number of subjects: 80
Study 11279374 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 1.5 g/kg (Group C)
Number of subjects: 80
Study 11279374 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 20 g (Group S)
Number of subjects: 80
Study 11279374 — intervention group
Group type: COMPARATOR
Intervention: NaCl 5 ml (Control Group F)
Number of subjects: 80
Study 9444564 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 lux dim white light exposure between 2400 hr and 0100 hr
Number of subjects: 0
Study 9444564 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 lux dim white light exposure between 2400 hr and 0100 hr
Number of subjects: 0
Study 9444564 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity light exposure
Number of subjects: 0
Study 8193000 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous vein patching
Number of subjects: 129
Study 8193000 — intervention group
Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 129
Study 8193000 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 129
Study 8193000 — intervention group
Group type: COMPARATOR
Intervention: Comparison of patch vs primary closure
Number of subjects: 129
Study 3249839 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg aminophylline aerosol
Number of subjects: 8
Study 3249839 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo aerosol
Number of subjects: 8
Study 29309737 — intervention group
Group type: EXPERIMENTAL
Intervention: green banana biomass alone
Number of subjects: 80
Study 29309737 — intervention group
Group type: EXPERIMENTAL
Intervention: green banana biomass plus sodium picosulfate
Number of subjects: 80
Study 29309737 — intervention group
Group type: EXPERIMENTAL
Intervention: green banana biomass plus PEG 3350 with electrolytes
Number of subjects: 80
Study 29309737 — intervention group
Group type: COMPARATOR
Intervention: PEG 3350 with electrolytes alone
Number of subjects: 80
Study 29309737 — intervention group
Group type: COMPARATOR
Intervention: sodium picosulfate alone
Number of subjects: 80
Study 28225446 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (CT) alone
Number of subjects: 270
Study 28225446 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy (RT) alone
Number of subjects: 270
Study 28225446 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy and radiation therapy (CRT)
Number of subjects: 270
Study 28225446 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy (RT)
Number of subjects: 270
Study 27084997 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil 100 mg in healthy subjects
Number of subjects: 18
Study 27084997 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil 75 mg in patients with mild HI
Number of subjects: 18
Study 27084997 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil 75 mg in patients with moderate HI
Number of subjects: 18
Study 23034875 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic electrodes (group M)
Number of subjects: 60
Study 23034875 — intervention group
Group type: COMPARATOR
Intervention: Osypka electrodes (group O)
Number of subjects: 60
Study 23034875 — intervention group
Group type: EXPERIMENTAL
Intervention: Both electrode types
Number of subjects: 60
Study 21613810 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c value of 6.9% for diagnosing diabetes mellitus
Number of subjects: 687
Study 21613810 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c cut-off points of 6.1%
Number of subjects: 687
Study 21613810 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c as an independent risk factor
Number of subjects: 687
Study 21613810 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in R wave in lead aVL
Number of subjects: 687
Study 21613810 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c as a predictor of cardiovascular disease
Number of subjects: 687
Study 21141286 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea treatment
Number of subjects: 0
Study 21141286 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 21141286 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment responders
Number of subjects: 0
Study 21141286 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment nonresponders
Number of subjects: 0
Study 17581943 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms assessed by the Geriatric Depression Scale (GDS‐15)
Number of subjects: 413
Study 17581943 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale (GDS‐15)
Number of subjects: 413
Study 16371745 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (beta-adrenergic blockade)
Number of subjects: 98
Study 16371745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 11905085 — intervention group
Group type: EXPERIMENTAL
Intervention: Dunaliella (natural)‐beta‐carotene supplementation for 3 weeks
Number of subjects: 15
Study 11905085 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 15
Study 11905085 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients (without supplementation)
Number of subjects: 15
Study 9469674 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF administration 24 hours after chemotherapy (standard arm)
Number of subjects: 25
Study 9469674 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF administration when ANC < 1000/mm3 (delayed arm)
Number of subjects: 25
Study 10150756 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxima 1380 oxygenator
Number of subjects: 32
Study 10150756 — intervention group
Group type: COMPARATOR
Intervention: Maxima Plus oxygenator
Number of subjects: 32
Study 2570601 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg (A50)
Number of subjects: 5
Study 2570601 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg (A100)
Number of subjects: 5
Study 2570601 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg (A200)
Number of subjects: 5
Study 2570601 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg (P40)
Number of subjects: 5
Study 2570601 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P1)
Number of subjects: 5
Study 327585 — intervention group
Group type: EXPERIMENTAL
Intervention: tolmetin (900 mg daily)
Number of subjects: 55
Study 327585 — intervention group
Group type: COMPARATOR
Intervention: aspirin (4 500 mg daily)
Number of subjects: 55
Study 327585 — intervention group
Group type: EXPERIMENTAL
Intervention: tolmetin
Number of subjects: 55
Study 31242669 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-containing dentifrices (group 1)
Number of subjects: 42
Study 31242669 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dentifrices containing 1450 ppm fluoride (group 2)
Number of subjects: 42
Study 31242669 — intervention group
Group type: COMPARATOR
Intervention: Natural dentifrices containing no chemical agent (group 3)
Number of subjects: 42
Study 29123255 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine plus bevacizumab (FP+Bev) maintenance treatment
Number of subjects: 871
Study 29123255 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 871
Study 27132052 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopy with treatment of detected intracavitary abnormalities before starting IVF (n=373)
Number of subjects: 750
Study 27132052 — intervention group
Group type: COMPARATOR
Intervention: Immediate start of IVF treatment (n=377)
Number of subjects: 750
Study 24379449 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (MT), 30 min twice a week for 6 weeks
Number of subjects: 36
Study 24379449 — intervention group
Group type: COMPARATOR
Intervention: Nonmassage sham treatment
Number of subjects: 36
Study 24379449 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (MT)
Number of subjects: 36
Study 21940484 — intervention group
Group type: EXPERIMENTAL
Intervention: G200 (200 mg/dL)
Number of subjects: 29
Study 21940484 — intervention group
Group type: COMPARATOR
Intervention: G100 (100 mg/dL)
Number of subjects: 29
Study 19171204 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive strength training
Number of subjects: 295
Study 19171204 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 295
Study 18021526 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 25
Study 18021526 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG treatment
Number of subjects: 25
Study 15885046 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.18-0.36 mg
Number of subjects: 11
Study 15885046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 16841622 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 300 mg once daily
Number of subjects: 248
Study 16841622 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided doses of modafinil 300 mg
Number of subjects: 248
Study 16841622 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg (200/200 mg) in children weighing >= 30 kg
Number of subjects: 248
Study 16841622 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200/100 mg
Number of subjects: 248
Study 16841622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 10370786 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum IL-10 levels (elevated > or = 10 pg/ml)
Number of subjects: 101
Study 10370786 — intervention group
Group type: COMPARATOR
Intervention: Normal serum IL-10 levels (below 10 pg/ml)
Number of subjects: 101
Study 10370786 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum IL-10 levels in Ann Arbor stage III or IV
Number of subjects: 101
Study 10370786 — intervention group
Group type: COMPARATOR
Intervention: Normal serum IL-10 levels in Ann Arbor stage III or IV
Number of subjects: 101
Study 8880049 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 12
Study 8880049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2068426 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplant treatment
Number of subjects: 0
Study 2068426 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 0
Study 6302612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (single intravenous daily dosage for 5 days)
Number of subjects: 30
Study 6302612 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime (three times daily for 5 days)
Number of subjects: 30
Study 31000792 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood mercury levels
Number of subjects: 20000
Study 31000792 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood lead levels
Number of subjects: 20000
Study 31000792 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cadmium levels
Number of subjects: 20000
Study 31000792 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood manganese levels
Number of subjects: 20000
Study 31000792 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood selenium levels
Number of subjects: 20000
Study 30066731 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral perfusion-targeted resuscitation
Number of subjects: 0
Study 30066731 — intervention group
Group type: COMPARATOR
Intervention: Lactate-targeted resuscitation
Number of subjects: 0
Study 27702718 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin with vitamin D (cholecalciferol 12,000 IU/week)
Number of subjects: 76
Study 27702718 — intervention group
Group type: COMPARATOR
Intervention: Renal multivitamin without vitamin D
Number of subjects: 76
Study 24889794 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine/cisplatin (GC)
Number of subjects: 114
Study 24889794 — intervention group
Group type: COMPARATOR
Intervention: Radical cystectomy alone
Number of subjects: 114
Study 22284243 — intervention group
Group type: EXPERIMENTAL
Intervention: Active patients (low or moderate-intensity physical activities >2 h/week)
Number of subjects: 247
Study 22284243 — intervention group
Group type: EXPERIMENTAL
Intervention: Active patients
Number of subjects: 247
Study 22284243 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 247
Study 20219000 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (Group B, n = 15)
Number of subjects: 45
Study 20219000 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% (Group L, n = 15)
Number of subjects: 45
Study 20219000 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% and Levobupivacaine 0.5%
Number of subjects: 45
Study 20219000 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% (Group L)
Number of subjects: 45